EarLens said it raised some $36 million in an equity round for the hearing aid technology it’s developing that uses infrared rather than sound waves.
The Redwood City, Calif.-based company, which is led by a former Abbott Vascular honcho, said 22 unnamed investors had participated in the round as of Feb. 24. EarLens is hoping to raise a total of $38.8 million, according to a regulatory filing.
EarLens is led by William Facteau, the former general manager of Abbott Vascular’s endovascular business, according to the EarLens site. Prior to joining EarLens as chairman, president & CEO in November 2013, Facteau was president of Acclarent, which Johnson & Johnson‘s (NYSE:JNJ) Ethicon divison bought for $785 million in 2010.
Chris Walker contributed to this report.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.